Loading...
Market
Story
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Adding Caplyta to Portfolio
Jan 13, 2025, 03:57 PM
Johnson & Johnson has announced the acquisition of Intra-Cellular Therapies Inc. for approximately $14.6 billion, marking the largest biotech deal in over a year. The deal involves a cash payment of $132 per share, representing a 39% premium over Intra-Cellular's closing stock price on the previous Friday. The acquisition aims to bolster Johnson & Johnson's portfolio in the treatment of central nervous system disorders, including schizophrenia, through the addition of Intra-Cellular's drug Caplyta. The transaction is expected to be completed within the year. This move comes amidst a backdrop of increased M&A activity in the pharmaceutical sector, spurred by upcoming patent expirations and a potentially more favorable regulatory environment under the incoming Trump administration.
View original story
Similar markets
Increases by more than 10% • 25%
Remains within 10% of current share • 25%
Other • 25%
Decreases by more than 10% • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
10% to 20% • 25%
5% to 10% • 25%
More than 20% • 25%
Less than 5% • 25%
Acquisition completed • 25%
No official outcome by end of 2025 • 25%
Acquisition abandoned • 25%
Acquisition delayed • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
Acquisition Completed • 25%
Other Outcomes • 25%